Antiviral Screening Services
Viral Infections
Pre-clinicalActive
Key Facts
About NeoVirTech
NeoVirTech is a specialized virology services and technology company built around its breakthrough ANCHOR™ imaging platform. This technology enables real-time, live-cell visualization of viral infection cycles, providing a powerful tool for high-content screening in antiviral discovery, validating oncolytic viruses, and measuring disinfection efficacy. Operating from BSL2 and BSL3 facilities, the company serves pharmaceutical, biotech, and academic clients worldwide with a portfolio of over 30 engineered viruses. Its business model is primarily service-based, positioning it as a critical enabler for the broader virology and antiviral therapeutics sector.
View full company profileTherapeutic Areas
Other Viral Infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Haptenized Viral Vaccines | BioVaxys | Preclinical |
| Cell-based Antiviral Drug Discovery Platform | Lucerna | Development |
| XAV19 | Xenothera | Preclinical |
| Anti-Viral Program | MicroQuin | Pre-clinical |
| Satiasolv | Marinomed Biotech | Pre-clinical |
| Telomir-1 | Telomir Pharmaceuticals | Pre-clinical |
| DehydraTECH for Antivirals | Lexaria Bioscience | Preclinical |
| RECCE® 529 | Recce Pharmaceuticals | Preclinical |